Gilead Sciences Announces Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Gilead Sciences (GILD) PT Lowered to $90 at Raymond James
February 5, 2019 9:00 AM ESTRaymond James analyst Steven Seedhouse lowered the price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $92.00) while maintaining a Strong Buy rating.
... MoreGilead Sciences (GILD) PT Lowered to $100 at Citi
February 5, 2019 6:59 AM ESTCiti analyst Robyn Karnauskas lowered the price target on Gilead Sciences (NASDAQ: GILD) to $100.00 (from $106.00) while maintaining a Buy rating. 2019 guidance anticipates double-digit y/y HIV growth and HCV stabilization. The company guided for generic impact in HCV, Letairis and Ranexa of ~$2.2B with... More
Gilead Sciences (GILD) PT Raised to $89 at RBC Capital
February 5, 2019 6:46 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Gilead Sciences (NASDAQ: GILD) to $89.00 (from $86.00) while maintaining a Outperform rating following fourth quarter results.
Abrahams commented, "Parsing out the one-time effects that inflated HIV but depressed earnings this quarter,... More
